You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations

  • Authors: Daniel A. Pollyea, MD, MS; Jorge E. Cortes, MD; Courtney D. DiNardo, MD, MSCE
  • CME / ABIM MOC Released: 5/1/2023
  • Valid for credit through: 5/1/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists.

The goal of this activity is for learners to be better able to identify treatment options for patients with AML without actionable targets and the management considerations for these patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Incidence and/or prognostic implications of non-targetable driver mutations in AML
    • Clinical trial data used to personalize treatment for patients with AML without targetable mutations
  • Have greater competence related to
    • Personalizing treatment for patients with AML without actionable targets 
  • Demonstrate greater confidence in their ability to
    • Select the appropriate therapy for patients with AML without actionable mutations


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Daniel A. Pollyea, MD, MS

    Professor of Medicine
    Clinical Director of Leukemia Services
    Associate Chief of Clinical Affairs
    Robert H. Allen MD Chair in Hematology Research
    Division of Hematology
    University of Colorado School of Medicine
    Aurora, Colorado

    Disclosures

    Daniel A. Pollyea, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Adicet; Aptevo; Arcellx; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Bergen Bio; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Dainippon Sumitomo Pharma America; Genentech; Gilead Sciences; Hibercell; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Karyopharm; Kura; Link; Magenta; Medivir; Novartis; Qihan; Rigel; Ryvu; Schrodeninger; Syndax Pharmaceuticals, Inc.; Syros; Zentalis
    Received research funding from: AbbVie Inc.; Bristol Myers Squibb Company; Karyopharm; Teva

  • Jorge E. Cortes, MD

    Professor and Director
    Georgia Cancer Center
    Augusta University
    Augusta, Georgia

    Disclosures

    Jorge E. Cortes, MD, has the following relevant financial relationships:
    Consultant or advisor for: Novartis; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda
    Research funding from: Novartis; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda

  • Courtney D. DiNardo, MD, MSCE

    Associate Professor
    Department of Leukemia
    Division of Cancer Medicine
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Courtney D. DiNardo, MD, MSCE, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Agios Pharmaceuticals; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Genentech; GenMab; Novartis; Notable Labs; Servier; Takeda
    Research funding from: AbbVie, Inc.; Agios Pharmaceuticals; Astex Pharmaceuticals; Bristol Myers Squibb Company; Calithera Biosciences; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Loxo Oncology; Servier
    Stock options from: Notable Labs

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships.  

  • Christin Melton, ELS

    Associate Medical Education Director, Medscape, LLC

    Disclosures

    Christin Melton, ELS, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations

Authors: Daniel A. Pollyea, MD, MS; Jorge E. Cortes, MD; Courtney D. DiNardo, MD, MSCEFaculty and Disclosures

CME / ABIM MOC Released: 5/1/2023

Valid for credit through: 5/1/2024, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to identify treatment options for patients with AML without actionable targets and the management considerations for these patients.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print